ICU Medical Announces Results of Study

ICU Medical, Inc.

today announced that a study presented this past weekend at the 36th annual meeting of the California Society of Health-System Pharmacists in Anaheim, CA has shown that the company's ChemoClave closed system transfer device designed to keep pharmacists, nurses and patients safe from accidental exposure to hazardous drugs is more affordable for hospitals to implement than any commercially available CSTD. The cost study, conducted by a team of researchers from Moores Cancer Center at the University of California San Diego Medical Center, reviewed all five commercially available CSTD systems: the ChemoClave by ICU Medical, Inc.; EquaShield by EquaShield Medical, Ltd.; OnGuard by B. Braun Medical, Inc.; PhaSeal® by Carmel Pharma, Inc.; and Texium/SmartSite by CareFusion Corp. To determine price, researchers included the actual number of components needed for a closed-system secondary infusion based on compounding techniques and intravenous administration set configuration in compliance with their institutional policies and practice guidelines. The cost of each individual component necessary to compound and administer a hazardous drug via a secondary infusion set for each CSTD was based on advertised prices at the time of the study, and individual component costs added together to generate a total cost for a single infusion. For indirect costs, researchers weighed the amount of waste generated by each system. Cost and waste totals for individual infusions were then multiplied by 15,312 infusions to generate an annual acquisition cost and waste per system.